{"title":"不要错过红斑狼疮","authors":"S. Soloway","doi":"10.5772/INTECHOPEN.96892","DOIUrl":null,"url":null,"abstract":"Chapter for Lupus Book Systemic lupus erythematosus is a well-recognized multi-system disease. Hallmarks of the disorder include the prevalence of antinuclear antibodies (ANA) and double stranded antibodies (DNA). The disease often presents with lupus rashes and/or arthritis or arthralgias. Lupus is “the great imitator,” as no organ system is excluded, when diagnosing and treating a lupus patient. While lupus remains evasive in novel therapies with true benefit; one issue has been consistent, in that the preponderance of the evidence thus far, leads to B cell dysfunction. More recently Belimumab was indicated for use in lupus patients. This is a BLyS-Specific inhibitor (B lymphocyte stimulator) medication. At this time, I would like to focus on lupus in a manner that you are not used to hearing. Typically, any practitioner who approaches a patient with a plethora of symptoms, would order blood tests, and conclude a diagnosis of lupus. In this chapter, I will point out and focus on the need to think “outside the box” and perhaps consider lupus as simply one of various other scenarios.","PeriodicalId":329276,"journal":{"name":"Lupus - Need to Know","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Don’t Miss Lupus\",\"authors\":\"S. Soloway\",\"doi\":\"10.5772/INTECHOPEN.96892\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chapter for Lupus Book Systemic lupus erythematosus is a well-recognized multi-system disease. Hallmarks of the disorder include the prevalence of antinuclear antibodies (ANA) and double stranded antibodies (DNA). The disease often presents with lupus rashes and/or arthritis or arthralgias. Lupus is “the great imitator,” as no organ system is excluded, when diagnosing and treating a lupus patient. While lupus remains evasive in novel therapies with true benefit; one issue has been consistent, in that the preponderance of the evidence thus far, leads to B cell dysfunction. More recently Belimumab was indicated for use in lupus patients. This is a BLyS-Specific inhibitor (B lymphocyte stimulator) medication. At this time, I would like to focus on lupus in a manner that you are not used to hearing. Typically, any practitioner who approaches a patient with a plethora of symptoms, would order blood tests, and conclude a diagnosis of lupus. In this chapter, I will point out and focus on the need to think “outside the box” and perhaps consider lupus as simply one of various other scenarios.\",\"PeriodicalId\":329276,\"journal\":{\"name\":\"Lupus - Need to Know\",\"volume\":\"5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lupus - Need to Know\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/INTECHOPEN.96892\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lupus - Need to Know","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.96892","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Chapter for Lupus Book Systemic lupus erythematosus is a well-recognized multi-system disease. Hallmarks of the disorder include the prevalence of antinuclear antibodies (ANA) and double stranded antibodies (DNA). The disease often presents with lupus rashes and/or arthritis or arthralgias. Lupus is “the great imitator,” as no organ system is excluded, when diagnosing and treating a lupus patient. While lupus remains evasive in novel therapies with true benefit; one issue has been consistent, in that the preponderance of the evidence thus far, leads to B cell dysfunction. More recently Belimumab was indicated for use in lupus patients. This is a BLyS-Specific inhibitor (B lymphocyte stimulator) medication. At this time, I would like to focus on lupus in a manner that you are not used to hearing. Typically, any practitioner who approaches a patient with a plethora of symptoms, would order blood tests, and conclude a diagnosis of lupus. In this chapter, I will point out and focus on the need to think “outside the box” and perhaps consider lupus as simply one of various other scenarios.